Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Coronavirus Screening Platform Uses Machine Learning Algorithms to Detect SARS-CoV-2 Structural Fingerprint in Real Time

By HospiMedica International staff writers
Posted on 27 Aug 2020
A screening platform that can identify biological threats by shining a laser onto the sample and interpreting the light that scatters is being used to develop a coronavirus screening platform, according to a report by BioSpace.

Botanisol Analytics (Phoenix, AZ, USA) is developing the screening platform that can identify biological threats, including contaminants and pathogens (such as the novel coronavirus), by shining a laser onto the sample. More...
The screener uses next generation Raman spectroscopy, which generates a unique structural ‘fingerprint’ for each molecule or even entire structures, such as whole cells or viruses. The laser interacts with the molecules in the sample, which absorb its energy and emit a higher or lower energy light. A detector collects the new light wavelengths that are emitted and turns them into digital input. A computer interprets the results to produce a Raman spectrum, the unique patterns of scattered light wavelengths represented as peaks. Artificial intelligence can then scan a spectrum to check for any unique patterns related to specific molecules or pathogens.

Using machine learning algorithms, the technology can identify salient differences between healthy and infected cells which could be present in an upper respiratory or saliva sample. As a coronavirus screener, the test output would be if someone is at low or high risk of carrying the virus, allowing people to be quickly grouped for release (low risk) or triage for further testing (high risk), according to BioSpace. The device could screen people for COVID-19 in real time, providing answers about what is in a sample in a matter of minutes. Botanisol’s ‘next generation’ system is also extremely sensitive and is able to detect something in the sample down to parts per million (ppm) or trillion (ppt), thanks to the use of a new type of laser that produces the smallest wavelength able to be transmitted through air under normal conditions, according to the BioSpace report.

“It’s a real-time snapshot of all the molecules in a patient’s sample,” David Talenfeld, JD, MBA, MGM, CEO of Botanisol, told BioSpace. “The device can be calibrated to detect a chemical or pathogen, like coronavirus, whose spectral ‘fingerprint’ is known."

“In the future you could take samples from people getting off of an airplane, quickly screening everyone,” added Talenfeld. “The people identified as ‘high risk’ for carrying coronavirus can be diverted to a special waiting area for further testing.”

Related Links:
Botanisol Analytics


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.